Lipodystrophy, Insulin Resistance, and Adiponectin Concentration in HIV-Infected Children and Adolescents

Vigan�, Alessandra; Zuccotti, Gian Vincenzo; Cerini, Chiara; Stucchi, Sara; Puzzovio, Maria; Giacomet, Vania; Mora, Stefano
July 2011
Current HIV Research;Jul2011, Vol. 9 Issue 5, p321
Academic Journal
Alterations of fat distribution and insulin resistance are associated with increased risk of metabolic derangements and cardiovascular disease. HIV-infected adult patients on antiretroviral treatment often show lipodystrophy, insulin resistance and hypoadiponectinemia, but data in children are controversial. We investigated serum adiponectin concentration in a cohort of HIV-infected youths, and we assessed the relationships with lipodystrophy and insulin resistance. We studied 36 HIV-infected patients (aged 5.0 - 19.4 years), and 171 healthy subjects (aged 4.9 - 17.9 years) for adiponectin measurements. All patients underwent body composition assessment by dual-energy x-ray absorptiometry, and an oral glucose tolerance test to determine the fasting insulin concentration, the insulin area under the curve (AUC), and the HOMA index. Adiponectin serum concentration was measured by an immunoenzymatic assay. Sixteen patients had central fat accumulation, 6 had peripheral lipoatrophy, 5 had a mixed phenotype, and the remaining 9 were non-lipodystrophic. Fasting insulin, insulin AUC, and HOMA index were significantly higher in patients with central fat adiposity and mixed phenotype than in the other two groups. The patients of the former two groups had adiponectin concentration much lower than healthy controls, and patients with peripheral lipoatrophy or normal phenotype had normal concentration. Low adiponectin concentration is associated to central fat and mixed lipohypertrophy, and to signs of insulin resistance in HIV-infected youths. Strict monitoring of metabolic and cardiovascular evolution should be performed in these patients.


Related Articles

  • Metabolic Effects of a Growth Hormone�Releasing Factor in Patients with HIV. Falutz, Julian; Allas, Soraya; Blot, Koenraad; Potvin, Diane; Kotler, Donald; Somero, Michael; Berger, Daniel; Brown, Stephen; Richmond, Gary; Fessel, Jeffrey; Turner, Ralph; Grinspoon, Steven // New England Journal of Medicine;12/6/2007, Vol. 357 Issue 23, p2359 

    Background: Visceral adipose tissue accumulates during antiretroviral therapy in many patients who are infected with the human immunodeficiency virus (HIV); this process is associated with an increased cardiovascular risk. We assessed the use of a growth hormone�releasing factor analogue,...

  • Lipodystrophy Syndrome by HAART in HIV-Infected Patients: Manifestation, Mechanisms and Management. Hirsch, H. H.; Battegay, M. // Infection;Oct2002, Vol. 30 Issue 5, p293 

    Progressive changes in the distributions of body fat and severe alterations of lipid, glucose and lactate levels challenge the mid and long-term success of highly active antiretroviral therapy of HIV-infection. Both clinical diagnosis of the lipodystrophy syndrome and scientific elucidation of...

  • The Role of Nutrition in Fat Deposition and Fat Atrophy in Patients with HIV. Dong, Kimberly R.; Hendricks, Kristy M. // Nutrition in Clinical Care;Jan-Mar2005, Vol. 8 Issue 1, p31 

    HIV-associated body shape changes and metabolic abnormalities, called HIV-associated lipodystrophy, are being seen with increased frequency. These issues may be associated with an increased risk of other diseases, such as cardiovascular disease, or with poor adherence to antiretroviral...

  • Long-term survival and interruption of HAART in HIV-related pulmonary hypertension. Zinkernagel, A.S.; von Overbeck, J.; Opravil, M.; Jenni, R.; Speich, R.; Mueller, N.J. // European Journal of Clinical Microbiology & Infectious Diseases;Feb2005, Vol. 24 Issue 2, p153 

    Reported here is a case of a patient with pulmonary arterial hypertension related to HIV (PAHRH) in which lipodystrophy necessitated interruption of highly active antiretroviral therapy (HAART) and long-term survival was the outcome. Although previous studies have suggested antiretroviral...

  • Antiretrovirals.  // Reactions Weekly;9/13/2008, Issue 1219, p8 

    The article presents a case study of a 37-year-old man who developed human immunodeficiency virus (HIV)-associated lipodystrophy syndrome while receiving various antiretrovirals for HIV. The patient also developed anaemia during zidovudine therapy, peripheral neuropathy while receiving...

  • Dysregulated Energy Expenditure in HIV-Infected Patients: A Mechanistic Review. Chang, Evelyn; Sekhar, Rajagopal; Patel, Sanjeet; Balasubramanyam, Ashok // Clinical Infectious Diseases;6/1/2007, Vol. 44 Issue 11, p1509 

    Metabolic abnormalities are common in patients with human immunodeficiency virus (HIV) infection and range from protein catabolism to lipodystrophy and dyslipidemia associated with the use of highly active antiretroviral therapy. One abnormality is increased resting energy expenditure, which ...

  • Skeletal muscle insulin signaling defects downstream of phosphatidylinositol 3-kinase at the level of Akt are associated with impaired nonoxidative glucose disposal in HIV lipodystrophy. Haugaard, Steen B.; Andersen, Ove; Madsbad, Sten; Frøsig, Christian; Iversen, Johan; Nielsen, Jens Ole; Wojtaszewski, Jørgen F. P.; Frøsig, Christian; Wojtaszewski, Jørgen F P // Diabetes;Dec2005, Vol. 54 Issue 12, p3474 

    More than 40% of HIV-infected patients on highly active antiretroviral therapy (HAART) experience fat redistribution (lipodystrophy), a syndrome associated with insulin resistance primarily affecting insulin-stimulated nonoxidative glucose metabolism (NOGM(ins)). Skeletal muscle biopsies,...

  • The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM): Methods, Design, and Sample Characteristics. Tien, Phyllis C.; Benson, Constance; Zolopa, Andrew R.; Sidney, Stephen; Osmond, Dennis; Grunfeld, Carl // American Journal of Epidemiology;May2006, Vol. 163 Issue 9, p860 

    The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM), initiated in 2000, investigates the prevalence and correlates of changes in fat distribution, insulin resistance, and dyslipidemia among human immunodeficiency virus (HIV)-infected men and women compared with a...

  • Lipoprotein(a) is not related to markers of insulin resistance in pregnancy. Todoric, Jelena; Handisurya, Ammon; Leitner, Karoline; Harreiter, Juergen; Hoermann, Gregor; Kautzky-Willer, Alexandra // Cardiovascular Diabetology;2013, Vol. 12 Issue 1, p1 

    Background: Dyslipidemia, a major risk factor for cardiovascular disease is a common finding in patients with type 2 diabetes and among women with gestational diabetes. Elevated levels of lipoprotein(a) [Lp(a)] are linked to increased risk of cardiovascular disease. However, its relationship...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics